Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices

Trial Profile

An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Richter's syndrome
  • Focus Adverse reactions
  • Sponsors Amgen

Most Recent Events

  • 28 Mar 2024 Status changed from active, no longer recruiting to completed.
  • 15 Jun 2023 Results of five year interim analysis assessing effectiveness and safety data of blinatumomab in these pts presented at the 28th Congress of the European Haematology Association
  • 23 Mar 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top